Abstract

BackgroundThe early but not the late phase of experimental inflammatory osteoarthritis (CiOA) is characterised by strongly elevated levels of S100A8/A91 and interleukin-1 beta (IL-1β).1,2 Adipose-derived mesenchymal stromal cells (ASCs) exhibit...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Local application of adipose-derived mesenchymal stromal cells in experimental inflammatory OA results in interleukin-1β-mediated attraction of PMNs and reduced S100A8/A9 release
B Walgreen ... M.M Van Helsen
Osteoarthritis and Cartilage | VOL. 25
B Walgreen, et. al.B Walgreen ... M.M Van Helsen
01 Apr 2017
SAT0004 Intra-articular injection of adipose-derived mesenchymal stromal cells reduce experimental oa pathology via il-1Β-mediated reallocation and enhanced phagocytosis of polymorphonuclear leucocytes
A Blom ... P Van Lent
Annals of the Rheumatic Diseases | VOL. 77
A Blom, et. al.A Blom ... P Van Lent
01 Jun 2018
IL-1β-Mediated Activation of Adipose-Derived Mesenchymal Stromal Cells Results in PMN Reallocation and Enhanced Phagocytosis: A Possible Mechanism for the Reduction of Osteoarthritis Pathology
Johannes Roth ... Arjen B Blom
Frontiers in Immunology | VOL. 10
Johannes Roth, et. al.Johannes Roth ... Arjen B Blom
27 May 2019
OP0146 Locally Administered Adipose Derived Mesenchymal Stem Cells Augment their Anti-Inflammatory Efficacy Through IL-1β Mediated Influx of Neutrophils into Knee Joints with Experimental Osteoarthritis
...
Annals of the Rheumatic Diseases | VOL. 74
, et. al. ...
01 Jun 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers